At a glance F ocused on serving people with rare diseases 2016 sales by therapeutic area Where we operate North America Genetic Diseases Neuroscience Latin America Europe Asia $2,698m $2,490m Hematology Internal Medicine Therapeutic area acquired with Baxalta onJune3, 2016 $2,241m $1,756m North America employees Immunology Oncology Therapeutic area acquired with Baxalta Therapeutic area acquired with Baxalta onJune3, 2016 onJune3, 2016 58% $1,516m $131m Ophthalmology $54m Financial highlights 4 Total revenue Product sales Non GAAP cash generation $11.4bn $10.9bn $3.5bn 1, 5 3 5 Non GAAP EBITDA Non GAAP operating income Non GAAP EBITDA margin $4.7bn $4.4bn 39% 2 Non GAAP adjusted ROIC 7% 2 Shire Annual Report 2016 R&D pipeline programs Preclinical Phase 1 Phase 2 Phase 3 Registration 35 6 10 17 4 Countries medicines available Employees 100 23,906 Group Headquarters Dublin, Ireland Europe employees U. S. Operational Headquarters Lexington, MA 35% International Operational Headquarters Zug, Switzerland Asia employees 5% Latin America employees 2% 1 This is a Non GAAP financial measure.
The most directly comparable measure under US GAAP isNetincome FY 2016: $327 million.
2 This is a Non GAAP financial measure.
Refer to Directors Remuneration Report on pages 82 to 113.
3 This is a Non GAAP financial measure.
The most directly comparable measure under US GAAP isOperating income from continuing operations FY 2016: $963 million.
4 This is a Non GAAP financial measure.
The most directly comparable measure under US GAAP isNetcash provided by operating activities FY 2016: $2,659 million.
5 Non GAAP earnings before interest, tax, depreciation and amortization EBITDA as a percentage ofproduct sales, excluding royalties and other revenues and cost of sales related to contract manufacturing revenue.
The most directly comparable measure under US GAAP is Net income FY2016: 3percent.
Results include legacy Baxalta since June 2016.
For a reconciliation of Non GAAP financial measures to the most directly comparable measure under US GAAP, see pages 185 to 187.
Shire Annual Report 2016 3 Other information Financial statements Governance Strategic report
